Upgrade to SI Premium - Free Trial

Organon (OGN)

13.42 -0.02 (0.15%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/11/26)

Latest Headlines

Form 4 Organon & Co. For: Jun 12 Filed by: Sharp Shalini June 15, 2026 4:42 PM - SEC Filing Form 4 Organon & Co. For: Jun 12 Filed by: Sequeira Ramona June 15, 2026 4:41 PM - SEC Filing Form 4 Organon & Co. For: Jun 12 Filed by: Patton Cynthia M June 15, 2026 4:40 PM - SEC Filing Form 4 Organon & Co. For: Jun 12 Filed by: Ozuah Philip June 15, 2026 4:39 PM - SEC Filing Form 4 Organon & Co. For: Jun 12 Filed by: Leone Deborah R June 15, 2026 4:38 PM - SEC Filing Form 4 Organon & Co. For: Jun 12 Filed by: LAZARUS ROCHELLE B June 15, 2026 4:37 PM - SEC Filing Form 4 Organon & Co. For: Jun 12 Filed by: Gayle Helene D June 15, 2026 4:35 PM - SEC Filing Form 4 Organon & Co. For: Jun 12 Filed by: Ezekowitz Alan June 15, 2026 4:34 PM - SEC Filing Form 4 Organon & Co. For: Jun 12 Filed by: ESSNER ROBERT June 15, 2026 4:32 PM - SEC Filing Organon gets FDA approval for expanded TOFIDENCE uses June 10, 2026 7:30 AM - StreetInsider Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19 June 10, 2026 7:30 AM - BizWire Organon to Present New Research on Access and Value at ISPOR 2026 May 15, 2026 7:30 AM - BizWire Form 4/A Organon & Co. For: May 06 Filed by: Holzbaur Lynette May 7, 2026 4:01 PM - SEC Filing Form 4 Organon & Co. For: May 06 Filed by: Holzbaur Lynette May 7, 2026 10:02 AM - SEC Filing Organon (OGN) Misses Q1 EPS by 12c April 30, 2026 7:44 AM - StreetInsider Organon Reports Results for the First Quarter Ended March 31, 2026 April 30, 2026 7:30 AM - BizWire European Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe April 29, 2026 10:00 AM - PR NewsWire Organon Cancels First Quarter Earnings Call April 29, 2026 7:30 AM - BizWire European commission approves first pertuzumab biosimilar in europe April 29, 2026 5:52 AM - StreetInsider European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe April 29, 2026 5:30 AM - BizWire BNP Paribas Exane Downgrades Organon & Co. (OGN) to Neutral Post Acquisition April 28, 2026 6:17 AM - StreetInsider Piper Sandler Upgrades Organon & Co. (OGN) to Neutral, raises PT April 27, 2026 4:25 PM - StreetInsider Increasing unusual option volume: QGEN OGN SGMT CMPX CAR April 27, 2026 9:48 AM - StreetInsider Sun Pharma to buy US drugmaker Organon for $11.75 billion in India's largest pharma deal April 27, 2026 1:19 AM - StreetInsider Sun Pharma To Buy Organon For $14/share Cash April 26, 2026 8:00 PM - StreetInsider Sun Pharma to acquire Organon for $14 per share in $11.75 billion deal April 26, 2026 7:51 PM - StreetInsider Sun Pharma signs Definitive Agreement to Acquire Organon April 26, 2026 7:51 PM - BizWire Increasing unusual put option volume: CAR WOLF WU BANC POET MDLN BB OGN ACLX SIDU April 24, 2026 10:39 AM - StreetInsider Organon To Report First Quarter 2026 Results and Host Conference Call on May 7, 2026 April 16, 2026 7:30 AM - BizWire Altius Provides 1st Quarter 2026 Project Generation Update April 15, 2026 12:48 PM - BizWire Organon's VTAMA cream gets strong recommendation in pediatric dermatitis guidelines April 15, 2026 7:30 AM - StreetInsider Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis April 15, 2026 7:30 AM - BizWire Sun Pharma denies material events related to Organon deal speculation April 10, 2026 7:58 AM - StreetInsider Form 4 Organon & Co. For: Mar 31 Filed by: Drinane Juliana Papa April 2, 2026 4:26 PM - SEC Filing Form 4 Organon & Co. For: Mar 31 Filed by: Arjona Ferreira Juan Camilo April 2, 2026 4:19 PM - SEC Filing Form 4 Organon & Co. For: Mar 31 Filed by: Karp Daniel April 2, 2026 4:18 PM - SEC Filing Form 4 Organon & Co. For: Mar 31 Filed by: Stahler Rachel A April 2, 2026 4:16 PM - SEC Filing Form 4 Organon & Co. For: Mar 31 Filed by: WALSH MATTHEW M April 2, 2026 4:13 PM - SEC Filing Form 4 Organon & Co. For: Mar 31 Filed by: Falcione Aaron April 2, 2026 4:11 PM - SEC Filing Form 4 Organon & Co. For: Mar 31 Filed by: Weaver Kirke April 2, 2026 4:10 PM - SEC Filing Form 4 Organon & Co. For: Mar 31 Filed by: Nisita Vittorio April 2, 2026 4:09 PM - SEC Filing Form 4 Organon & Co. For: Mar 31 Filed by: Holzbaur Lynette April 2, 2026 4:07 PM - SEC Filing Form 4 Organon & Co. For: Mar 31 Filed by: Morrissey Joseph T. Jr. April 2, 2026 4:03 PM - SEC Filing Form 4 Organon & Co. For: Mar 29 Filed by: Stahler Rachel A March 31, 2026 4:19 PM - SEC Filing Form 4 Organon & Co. For: Mar 29 Filed by: Holzbaur Lynette March 31, 2026 4:17 PM - SEC Filing Form 4 Organon & Co. For: Mar 29 Filed by: Karp Daniel March 31, 2026 4:15 PM - SEC Filing Form 4 Organon & Co. For: Mar 29 Filed by: Weaver Kirke March 31, 2026 4:13 PM - SEC Filing Form 4 Organon & Co. For: Mar 29 Filed by: Nisita Vittorio March 31, 2026 4:12 PM - SEC Filing Form 4 Organon & Co. For: Mar 29 Filed by: Drinane Juliana Papa March 31, 2026 4:11 PM - SEC Filing Form 4 Organon & Co. For: Mar 29 Filed by: Arjona Ferreira Juan Camilo March 31, 2026 4:11 PM - SEC Filing Form 4 Organon & Co. For: Mar 29 Filed by: Falcione Aaron March 31, 2026 4:09 PM - SEC Filing Form 4 Organon & Co. For: Mar 29 Filed by: WALSH MATTHEW M March 31, 2026 4:08 PM - SEC Filing Form 4 Organon & Co. For: Mar 29 Filed by: Morrissey Joseph T. Jr. March 31, 2026 4:07 PM - SEC Filing Organon presents new VTAMA cream data showing early atopic dermatitis improvement March 27, 2026 8:01 AM - StreetInsider Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years o March 27, 2026 8:00 AM - BizWire Full Article List